Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Human immunodeficiency virus (HIV) infection Clinical criteria: The treatment must be in addition to optimised background therapy, AND The treatment must be in combination with other antiretroviral agents, AND The treatment must be co-administered with 100 mg ritonavir twice daily, AND Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen. Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.
“Darunavir is an inhibitor of the dimerisation and of the catalytic activity of the HIV-1 protease. It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles.”
“15 hours (with ritonavir)”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.